特布他林雾化吸入联合阿奇霉素治疗小儿支原体肺炎的临床效果及对炎性因子水平的影响

The clinical effect of terbutaline nebulized inhalation combined with azithromycin therapy in the treatment of mycoplasma pneumonia in children and its influence on the level of inflammatory factors

目的:探讨特布他林雾化吸入联合阿奇霉素序贯疗法治疗小儿支原体肺炎的临床效果及对炎性因子水平的影响。方法:2019年3月-2020年5月收治小儿支原体肺炎患儿94例,随机分为两组,各47例。对照组给予阿奇霉素序贯疗法;观察组在阿奇霉素基础上应用特布他林雾化吸入。比较两组患儿临床效果及炎性因子水平。结果:观察组治疗总有效率显著高于对照组,差异有统计学意义(P<0.05);观察组治疗后肿瘤坏死因子-α(TNF-α)、C-反应蛋白(CRP)、白细胞介素-6(IL-6)水平均低于对照组,差异有统计学意义(P<0.05);观察组退热时间、啰音消失时间、咳嗽消失时间及胸部X线片恢复正常时间均显著短于对照组,差异有统计学意义(P<0.05)。结论:特布他林雾化吸入联合阿奇霉素序贯疗法治疗小儿支原体肺炎的效果显著,可有效控制患儿机体内炎性因子水平,改善临床症状。

Objective:To investigate the clinical effect of terbutaline nebulized inhalation combined with azithromycin sequential therapy in the treatment of mycoplasma pneumonia in children and its influence on the level of inflammatory factors.Methods:From March 2019 to May 2020,94 children with mycoplasma pneumonia were selected,they were randomly divided into the two groups with 47 cases in each group.The control group was given azithromycin therapy.The observation group was given azithromycin and terbutaline nebulized inhalation.The clinical effects and levels of inflammatory factors were compared between the two groups of children.Results:The total effective rate of treatment in the observation group was significantly higher than that in the control group,the difference was statistically significant(P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α),C-reactive protein(CRP)and interleukin-6(IL-6)in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).The time of fever reduction,the disappearance of rales,the disappearance of cough,and the recovery time of chest X-ray in the observation group were significantly shorter than those in the control group,the difference is statistically significant(P<0.05).Conclusion:Terbutaline nebulized inhalation combined with azithromycin sequential therapy has satisfactory results in the treatment of mycoplasma pneumonia in children,which can effectively control the level of inflammatory factors in the patient's body and improve clinical symptoms.